Online inquiry

IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5858MR)

This product GTTS-WQ5858MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5858MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2406MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 110
GTTS-WQ10773MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M-70
GTTS-WQ13308MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ14309MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-7221
GTTS-WQ8174MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HL161
GTTS-WQ16005MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ7521MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GC-1102
GTTS-WQ14924MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Shigamabs®
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW